Dyne Therapeutics, Inc., a clinical-stage company dedicated to creating life-transforming therapeutics for individuals with genetically driven diseases, has announced plans to disclose new clinical data from its Phase 1/2 ACHIEVE clinical trial. The announcement is scheduled for January 10, 2025, accompanied by a webcast at 8:00 a.m. ET. A press release will precede the event.
The live webcast will be accessible on the Events & Presentations page within the Investors & Media section of Dyne’s website, with a replay available for 90 days post-presentation. An accompanying slide presentation will also be provided. For access to the live webcast and replay, visit Dyne Therapeutics' Events & Presentations.
Dyne Therapeutics is at the forefront of discovering and advancing innovative therapeutics for genetically driven neuromuscular diseases. Utilizing its FORCE™ platform, the company is developing targeted treatments aimed at overcoming delivery challenges to muscle tissue and the central nervous system (CNS). Its pipeline includes clinical programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).
